These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence.
    Author: Revicki DA.
    Journal: Curr Opin Investig Drugs; 2001 Jan; 2(1):110-7. PubMed ID: 11527002.
    Abstract:
    A comprehensive evaluation of atypical antipsychotics for the treatment of schizophrenia involves documentation of clinical effectiveness, quality of life and medical cost outcomes. The results of pharmacoeconomic studies assist psychiatrists, and other healthcare decision-makers, in identifying pharmacotherapies that provide the greatest benefit to patients at the most acceptable cost. The cost-effectiveness of the newer atypical antipsychotics has been examined using clinical decision-modeling studies and randomized clinical trials. The research evidence suggests that clozapine is a cost-effective treatment for neuroleptic refractory schizophrenia. Olanzapine and risperidone may be cost-neutral or, at best, slightly cost-saving compared with conventional antipsychotics, although they do improve clinical symptoms and quality of life outcomes. There is insufficient published data on pharmacoeconomic outcomes for sertindole, quetiapine and ziprasidone to make any conclusions about their cost-effectiveness in treating schizophrenia.
    [Abstract] [Full Text] [Related] [New Search]